DMTweet: a psychedelic tweet recap

a PsyMed Ventures x Business Trip colab (issue #6)

DMTweet is a newsletter of psychedelic tweets that catch our eye 👀.

This is a collaboration between PsyMed Ventures and Business Trip (yes, we’re the folks working on both 🙃).

Tweets include: Industry updates 💼, Therapy 🛋️, Psychedelic research 🧪, Neuroscience 🧠, Consciousness ✨, Indigenous reciprocity ⚖️, Regulatory updates 📜, and Trippy ideas 👽.

Inclusion = interesting ≠ endorsement.

Let’s get to it….

Zeus Tipado @tipado

It's crazy people don't know this, but 5-MeO-DMT was first synthesized by Toshio Hoshino at Tokyo Institute of Tech on 1936 -- two years *before* Hoffman synthesized LSD. One scientist got a Bicycle Day, the other just forgotten. Props to Hoshino for paving the DMT pathway🤘🏽

Balazs Szigeti @psybalazs

In most places one month #SSRI supply is cheaper than an hour of therapy. If #psychedelics #therapy requires therapist(s) to sit through the long trips, as it is currently tested, that will skyrocket the costs. Has anyone written about this cost/scalability issue of psy therapy?

Dr. K8 PsyD @psych_k8

Therapists are wary of tech companies for many reasons, because they’ve seen clients harmed by businesses attempting to capitalize on a mental health crisis. Building trust is a slow but absolutely vital process for these companies—many aren’t willing to put in the time + effort

Manoj Doss not exist @ManojDoss

MDMA reduces fear memory but only when paired w/a trauma cue. More evidence that external cues may improve MDMA therapy (was somewhat 5-HT2A dependent so may also apply to proper psychedelics) and we shouldn't rely on hippie notions like the "inner healer"

nature.comMDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats - Translational Psychia…Translational Psychiatry - MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats

Aaron Weiner, PhD, ABPP @WeinerPhD

A new @nytimes article today highlights that #overdose deaths are now up to 108,000. This is a MASSIVE problem, and we need to be vocal about solutions. I've written about this in the past (link down in 🧵) - our primary intervention areas need to be: tinyurl.com/3dnsdtzc

Andy Mychkovsky 🍕 @healthcareandy

What is the biggest lie / scam about US healthcare? Genuinely curious for the answers.

PsyMed Ventures @PsymedVentures

Psychedelic biotech companies are seemingly popping up left and right over the last couple of years. What makes one a worthy investment? 🧐 @matisere and @kubeans published an article on @TechCrunch talking about how we evaluate companies here at @PsymedVentures! 🧵⬇️

Calley Hair @CalleyNHair

Starting on Jan. 2, psilocybin - aka the psychedelic in magic mushrooms - will come to OR. But what will that actually look like, & who is it for? I wrote an FAQ on the messy intersection of politics, capitalism, science & equity for the @portlandmercury

portlandmercury.comOregon Has Legalized Psilocybin Therapy—So When Can I Take Magic Mushrooms?It’s T-minus 259 days until Oregonians can legally start tripping, and we’re still deciding how best to manage the production and administration of psychedelic drugs. In 2020, voters passed Measure 109, permitting the use of psilocybin, the active ingredient in magic mushrooms. In the months since,…

Alex Garcia @alex_here_now

(watching psychedelic stocks dip) you see, there are no bad investments. only ✨challenging investment experiences✨

Until next time,

Greg, Matias, and Dina

🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄

DMTweet is a collab between PsyMed Ventures and Business Trip. PsyMed Ventures is a community-focused fund and syndicate investing in psychedelic medicine and mental health tech. Business Trip is a podcast about psychedelic entrepreneurship. Our mission is to help expand access to psychedelic medicine and mental health.